Groundbreaking Partnership for Early Cancer Detection

Dongwoon Anatech, a leading Korean fabless semiconductor company, has embarked on a pioneering joint research initiative with the University of California, Los Angeles (UCLA). This collaboration focuses on developing a revolutionary saliva-based diagnostic platform for the early detection of various cancers, including lung, stomach, and oral cancer, as well as autoimmune diseases.

EFIRM Technology: A Leap Forward in Non-Invasive Diagnostics

The partnership will leverage the electric field-induced release and measurement (EFIRM) technology, developed by Dr. David Wong's team at UCLA, in conjunction with Dongwoon Anatech’s semiconductor expertise. This innovative platform aims to make disease diagnosis faster, simpler, and more accessible globally.

Securing Global Regulatory Approval

Together, they will also work on securing data for global regulatory approval clinical trials for "D-SaLife," a saliva-based blood glucose monitoring system. Utilizing UCLA's vast repository of multi-ethnic saliva samples, the collaboration aims to validate the safety and efficacy of D-SaLife, ensuring its readiness for the U.S. Food and Drug Administration (FDA) submission.

A Shared Vision for the Future

"This collaboration reflects our shared vision to make disease diagnosis faster, simpler, and more accessible to everyone worldwide," stated Prof. Wong. Kim Dong-cheol, CEO of Dongwoon Anatech, emphasized the importance of UCLA's saliva samples in achieving their goals, highlighting the potential to pioneer new markets in early disease diagnosis.